Eli Lilly , Novo Nordisk shares slide after CBO comments on obesity drugs
Eli Lilly (LLY), Novo Nordisk (NVO) shares slide after CBO comments on obesity drugs
LLY
-0.48%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
NVO
-0.57%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
Shares of pharmaceutical companies Eli Lilly & Co. (NYSE:LLY) and Novo Nordisk (NYSE:NVO) dipped slightly Wednesday in reaction to comments from Congressional Budget Office analysts.
It was reported by Bloomberg that the Congressional Budget Office analysts said at a conference that obesity drugs would raise the US deficit over 10 years.
Eli Lilly shares are down around 0.8% at $766.30 per share as of 13:32 ET on Wednesday. Earlier in the session, the stock hit a low of $756.64. Even so, LLY shares are up almost 32% in 2024, while they have gained an impressive 129% over the last 12 months.
Novo Nordisk shares have also slipped Wednesday, currently trading 0.75% lower at $130.39 per share.
Analysts are said to have stated that obesity drugs would cost the US more than anticipated savings.
